<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bournakis, E.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Varkaris, A.</style></author><author><style face="normal" font="default" size="100%">Wen, S.</style></author><author><style face="normal" font="default" size="100%">Chrisofos, M.</style></author><author><style face="normal" font="default" size="100%">Deliveliotis, C.</style></author><author><style face="normal" font="default" size="100%">Alamanis, C.</style></author><author><style face="normal" font="default" size="100%">Anastasiou, I.</style></author><author><style face="normal" font="default" size="100%">Constantinides, C.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Advanced prostate cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Castrate-resistant prostate cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Predictors of survival</style></keyword><keyword><style  face="normal" font="default" size="100%">Time to castration resistance</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79956136146&amp;partnerID=40&amp;md5=534e040ad8b7c3cd6c3172341ed1ac7f</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">1475 - 1482</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background/Aim: Easily assessable clinical predictors of response to chemotherapy in advanced castration-resistant prostate cancer (CRPC) are few. The objective of this retrospective study was to search for and identify such candidate predictors of outcome. Patients and Methods: A retrospective analysis of clinical data of CRPC patients entered in the Clinical Therapeutics' departmental prostate cancer database from 1996-2009 was performed. Univariate and multivariate analyses for progression-free survival and overall survival included patients receiving both docetaxel- and non-docetaxel-containing regimens. Results: From 1996 until June 2009, 286 out of 313 patients in our database were treated with chemotherapy. Prostate-specific antigen (PSA) reduction &gt;30% correlated with improved survival irrespective of treatment. Beyond previously reported predictors, i.e. baseline PSA&gt;30 ng/dl, hemoglobin below 10 mg/dl, weight loss, poor performance status, elevated lactic dehydrogenase and alkaline phosphatase, and time to CRPC of less than or equal to two years was associated with a poor overall survival and shorter progression-free survival upon univariate analysis. Pain was associated with shorter survival. Multivariate analysis confirmed time to CRPC, lactate dehydrogenase and alkaline phosphatase as independent predictors of overall and progression-free survival. Conclusion: Time to castration resistance is an important predictor of outcome in CRPC. PSA reduction &gt;30% predicts survival improvement following chemotherapy for CRPC regardless of chemotherapy applied.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :4Export Date: 21 February 2017</style></notes></record></records></xml>